A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation
Yutaka Matsuda(Ajinomoto (United States)), Brian A. Mendelsohn(Seagen (United States)), Tatsuya Okuzumi(Suzuki (Japan)), Monica Leung(Ajinomoto (United States))
Cited by 36
Related Papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
|Bioconjugate Chemistry|2005|511
Inhibitor hijacking of Akt activation
|Nature Chemical Biology|2009|296
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
|Breast Cancer Research|2009|156
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production
|Bioconjugate Chemistry|2023|62